Browse by Audience
MEMBER

Update Your Profile
Member Spotlights
Refer a Member: IASP Champions
Join a Special Interest Group (SIG)
Find a Chapter
Join Now

RESEARCHER

PAIN
PAIN Reports
Pain Research Forum
Papers of the Week
Webinars and Podcasts
Events

HEALTH CARE PROVIDER

Online Learning - PERC
Webinars & Podcasts
Curricula
Graduate Opportunities
Events

PATIENT & CAREGIVER

RELIEF News
Resources for Living with Pain
Global Alliance of Partners in Pain Advocacy (GAPPA)
Events

PARTNER

Support IASP
Sponsor an Event
Become a Partner

gy2022-1-3
I am a
IASP Logo
Home I AM A Search Login

Papers of the Week

Home / Publications / Pain Research Forum / Papers of the Week / Real-world efficacy, tolerability, and safety of ubrogepant.

< BACK TO ARCHIVE


Papers: 6 Feb 2021 - 12 Feb 2021


Human Studies, Pharmacology/Drug Development

PAIN TYPE:
Migraine/Headache


2021 Feb 05


Headache


http://www.ncbi.nlm.nih.gov/pubmed/33547676?dopt=Abstract

Real-world efficacy, tolerability, and safety of ubrogepant.

Authors

Real-world efficacy, tolerability, and safety of ubrogepant.
Chiang C-C, Arca KN, Dunn RB, Girardo ME, Quillen JK, Dodick DW, Starling AJ
Headache. 2021 Feb 05.
PMID: 33547676.

Abstract

To assess the real-world efficacy, tolerability, and safety of ubrogepant in a tertiary headache center.
Read This Paper